Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Hyaluronic acid + ginkgo biloba** is a preservative-free ophthalmic combination product marketed as **TRIUM** for ocular surface disorders, particularly dry eye disease, allergic conjunctivitis, and post-traumatic ocular surface alterations. The formulation contains **0.15% sodium hyaluronate** and **0.05% ginkgo biloba extract** and is developed/manufactured by **Fidia Farmaceutici** and distributed by **SOOFT Italy**. Its therapeutic effect is primarily local and non-target-based: hyaluronic acid acts as a viscoelastic tear substitute and lubricant that hydrates, protects, and stabilizes the ocular surface and tear film, while ginkgo biloba extract is used for antioxidant and protective support against ocular surface irritation and inflammation. It is best characterized as a **topical ophthalmic medical device combination product** rather than a conventional small-molecule or biologic drug. Clinical evidence cited for the combination includes use after cataract surgery, where adjunctive HA-GB eye drops improved tear break-up time, symptoms, conjunctival hyperemia, and tolerability versus standard postoperative care alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyaluronic acid + ginkgo biloba.